GeneMedicine is developing next-generation viral immunotherapies to treat patients with refractory cancers. By utilizing engineered oncolytic viruses, the company aims to enhance immune responses against tumors, improving patient outcomes and quality of life.
Funding
$15M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many cancers become refractory to standard treatments, requiring novel therapeutic approaches. Traditional cancer treatments often fail to elicit a sufficient immune response to eradicate tumors, leading to recurrence and poor patient outcomes.
Solution
GeneMedicine is developing engineered oncolytic viruses designed to selectively infect and destroy cancer cells while simultaneously stimulating a robust anti-tumor immune response. These next-generation viral immunotherapies aim to overcome resistance mechanisms and improve outcomes for patients with refractory cancers. The engineered viruses are designed to enhance the body's natural ability to recognize and eliminate cancer cells, potentially leading to more durable remissions and improved quality of life. By targeting the tumor microenvironment and activating immune cells, GeneMedicine's approach seeks to provide a more effective and targeted treatment option.
Target Audience
The primary target audience includes patients with refractory cancers who have failed to respond to standard treatments, as well as oncologists and researchers seeking novel immunotherapeutic approaches.
Features
- Engineered oncolytic viruses with enhanced tumor selectivity and immune-stimulatory properties
- Development of viral vectors for targeted delivery of therapeutic genes to cancer cells
- Preclinical studies demonstrating efficacy in refractory cancer models